サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1536136

心筋梗塞（MI）治療の世界市場

Myocardial Infarction (MI) Treatment

出版日
ページ情報
英文 296 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
心筋梗塞（MI）治療の世界市場
出版日: 2024年08月16日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 296 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

心筋梗塞（MI）治療の世界市場は2030年までに21億米ドルに達する見込み

2023年に17億米ドルと推定される心筋梗塞（MI）治療の世界市場は、分析期間2023-2030年にCAGR 3.0%で成長し、2030年には21億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである抗血小板剤は、CAGR 3.9%を記録し、分析期間終了時には9億5,460万米ドルに達すると予測されます。糖タンパク質IIb/IIIa阻害剤セグメントの成長率は、分析期間中CAGR 2.9％と推定されます。

米国市場は推定4億6,980万米ドル、中国はCAGR6.0％で成長予測

米国の心筋梗塞（MI）治療市場は、2023年に4億6,980万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに4億3,490万米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは6.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.8%と2.3%と予測されています。欧州では、ドイツがCAGR 1.5%で成長すると予測されています。

世界の心筋梗塞（MI）治療市場- 主要動向と促進要因まとめ

一般に心臓発作として知られる心筋梗塞（MI）は、心臓の一部への血流が長時間遮断され、心筋の一部が損傷または死滅した場合に発症します。心筋梗塞の最も一般的な原因は、冠動脈の壁に脂肪が蓄積してプラークを形成することです。このプラークが破裂すると血栓が形成され、血流が阻害されます。血流を回復させ、心臓の損傷を最小限に抑えるためには、早急な治療が重要です。心筋梗塞の主な治療には、抗血小板薬、抗凝固薬、血栓溶解薬、β遮断薬、ACE阻害薬などの薬剤が用いられます。これらの薬剤は血栓を溶かし、心臓の仕事量を減らし、血栓のさらなる形成を防ぐのに役立ちます。薬物療法に加えて、閉塞した動脈を再開通させて血流を回復させるためには、血管形成術やステント留置術、冠動脈バイパス術（CABG）などの侵襲的な処置が必要になることも多いです。

技術の進歩により、心筋梗塞の治療成績は著しく向上しました。動脈の再閉塞を防ぐ薬剤を放出する薬剤溶出ステントの開発は，血管形成術に革命をもたらしました。さらに，血管内超音波（IVUS）や光干渉断層計（OCT）のような高度な画像診断技術の使用により，動脈の閉塞を正確に評価し，より良い治療計画を立てることができるようになった。遠隔医療や遠隔モニタリングの技術も，ヘルスケアプロバイダーが患者の心臓の状態をより詳細にモニターし，心筋梗塞の徴候に迅速に対応することを可能にしました。さらに，運動トレーニング，食事カウンセリング，心理的サポートなどを含む包括的な心臓リハビリテーションプログラムの実施は，心筋梗塞患者の長期的転帰とQOLの改善に有効であることが証明されています。

心筋梗塞治療市場の成長はいくつかの要因によってもたらされます。低侵襲手術技術やより効果的な薬物療法の開発など、医療技術の進歩が市場拡大を後押ししています。また、高齢化や食生活の乱れ、運動不足、喫煙などのライフスタイル要因による心血管疾患の有病率の増加も、心筋梗塞治療に対する需要を押し上げています。さらに、公衆衛生への取り組みや教育キャンペーンに支えられた早期診断・早期介入の重要性に対する意識の高まりが、よりタイムリーで効果的な治療につながっています。遺伝的、環境的、生活習慣的要因に基づいて個々の患者のプロファイルに合わせた治療計画を立てる個別化医療の台頭も重要な促進要因です。継続的なモニタリングと心臓問題の早期発見を容易にするウェアラブル健康技術やモバイル健康アプリケーションの革新は、市場の成長にさらに寄与しています。さらに、先進地域の強固なヘルスケア・インフラと新興国市場のヘルスケア・サービスへのアクセス向上が、MI治療の裾野を広げています。ヘルスケアプロバイダーが新しい技術や方法を採用し続けることで、心筋梗塞治療市場は持続的な成長を遂げると予想されます。

調査対象企業の例（全86件）

  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Amgen, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Bayer AG
  • Biocardia, Inc.
  • Boehringer Ingelheim International GmbH
  • CellProthera
  • CSL Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Faraday Pharmaceuticals
  • Kancera AB
  • Nordic Bioscience A/S
  • Tenaya Therapeutics
  • Viatris Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP26667

Global Myocardial Infarction (MI) Treatment Market to Reach US$2.1 Billion by 2030

The global market for Myocardial Infarction (MI) Treatment estimated at US$1.7 Billion in the year 2023, is expected to reach US$2.1 Billion by 2030, growing at a CAGR of 3.0% over the analysis period 2023-2030. Antiplatelet Agents, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$954.6 Million by the end of the analysis period. Growth in the Glycoprotein IIb / IIIa Inhibitors segment is estimated at 2.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$469.8 Million While China is Forecast to Grow at 6.0% CAGR

The Myocardial Infarction (MI) Treatment market in the U.S. is estimated at US$469.8 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$434.9 Million by the year 2030 trailing a CAGR of 6.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 2.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.

Global Myocardial Infarction (MI) Treatment Market - Key Trends and Drivers Summarized

Myocardial infarction (MI), commonly known as a heart attack, occurs when blood flow to a part of the heart is blocked for a long enough time that part of the heart muscle is damaged or dies. The most common cause of MI is the buildup of fatty deposits on the walls of coronary arteries, which form plaques. When these plaques rupture, a blood clot can form and obstruct the blood flow. Immediate treatment is crucial to restore blood flow and minimize heart damage. The primary treatment for MI includes medications such as antiplatelets, anticoagulants, thrombolytics, beta-blockers, and ACE inhibitors. These drugs help dissolve clots, reduce the heart's workload, and prevent further clot formation. In addition to medication, invasive procedures like angioplasty and stent placement, as well as coronary artery bypass grafting (CABG), are often necessary to reopen blocked arteries and restore blood flow.

Advancements in technology have significantly improved the outcomes of MI treatment. The development of drug-eluting stents, which release medication to prevent artery re-blockage, has revolutionized angioplasty procedures. Moreover, the use of advanced imaging techniques such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT) allows for precise assessment of arterial blockages and better planning of interventions. Telemedicine and remote monitoring technologies have also made it possible for healthcare providers to monitor patients' heart health more closely and respond quickly to signs of a potential MI. Furthermore, the implementation of comprehensive cardiac rehabilitation programs, which include exercise training, dietary counseling, and psychological support, has proven to be effective in improving the long-term outcomes and quality of life for MI patients.

The growth in the myocardial infarction treatment market is driven by several factors. Advances in medical technology, such as the development of minimally invasive surgical techniques and more effective drug therapies, are propelling market expansion. The increasing prevalence of cardiovascular diseases due to aging populations and lifestyle factors like poor diet, lack of exercise, and smoking is also driving demand for MI treatments. Additionally, heightened awareness about the importance of early diagnosis and intervention, supported by public health initiatives and education campaigns, is leading to more timely and effective treatments. The rise of personalized medicine, which tailors treatment plans to individual patient profiles based on genetic, environmental, and lifestyle factors, is another significant driver. Innovations in wearable health technologies and mobile health applications that facilitate continuous monitoring and early detection of heart issues are further contributing to market growth. Moreover, robust healthcare infrastructure in developed regions and improving access to healthcare services in emerging markets are expanding the reach of MI treatments. As healthcare providers continue to adopt new technologies and methods, the market for myocardial infarction treatments is expected to experience sustained growth.

Select Competitors (Total 86 Featured) -

  • A. Menarini Industrie Farmaceutiche Riunite Srl
  • Amgen, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Bayer AG
  • Biocardia, Inc.
  • Boehringer Ingelheim International GmbH
  • CellProthera
  • CSL Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Faraday Pharmaceuticals
  • Kancera AB
  • Nordic Bioscience A/S
  • Tenaya Therapeutics
  • Viatris Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Myocardial Infarction (MI) Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Cardiovascular Diseases Expands Addressable Market Opportunity
    • Advances in Minimally Invasive Surgical Techniques Propel Growth
    • Development of Effective Drug Therapies Strengthens Business Case for Treatment Adoption
    • Aging Population and Lifestyle Factors Drive Demand for MI Treatments
    • Heightened Awareness of Early Diagnosis and Intervention Spurs Market Expansion
    • Rise of Personalized Medicine Strengthens Business Case for Customized Treatments
    • Mobile Health Applications Facilitate Continuous Monitoring and Drive Adoption
    • Robust Healthcare Infrastructure in Developed Regions Sustains Growth
    • Improving Access to Healthcare Services in Emerging Markets Expands Reach
    • Technological Advancements in Imaging Techniques Enhance Treatment Precision
    • Increasing Utilization of Telemedicine Throws the Spotlight on Remote Monitoring
    • Enhanced Patient Outcomes with Drug-Eluting Stents Drive Market Adoption
    • Implementation of Artificial Intelligence in Diagnosis and Treatment Planning Spurs Growth
    • Focus on Reducing Healthcare Costs Through Effective MI Management Expands Market Opportunity
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Myocardial Infarction (MI) Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Myocardial Infarction (MI) Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Myocardial Infarction (MI) Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antiplatelet Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antiplatelet Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Antiplatelet Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Glycoprotein IIb / IIIa Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Glycoprotein IIb / IIIa Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Glycoprotein IIb / IIIa Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Antithrombotic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Antithrombotic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Antithrombotic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Beta-Adrenergic Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Beta-Adrenergic Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Beta-Adrenergic Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Drug Stores by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Drug Stores by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Drug Stores by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • JAPAN
    • Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • CHINA
    • Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: China 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • EUROPE
    • Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Myocardial Infarction (MI) Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Myocardial Infarction (MI) Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • FRANCE
    • Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: France 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • GERMANY
    • Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Myocardial Infarction (MI) Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Myocardial Infarction (MI) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • INDIA
    • Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: India 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: India 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Myocardial Infarction (MI) Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Myocardial Infarction (MI) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Myocardial Infarction (MI) Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Myocardial Infarction (MI) Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030
  • AFRICA
    • Myocardial Infarction (MI) Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Myocardial Infarction (MI) Treatment by Drug Type - Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Myocardial Infarction (MI) Treatment by Drug Type - Percentage Breakdown of Value Sales for Antiplatelet Agents, Glycoprotein IIb / IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers and Other Drug Types for the Years 2014, 2024 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Myocardial Infarction (MI) Treatment by Distribution Channel - Hospital Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Myocardial Infarction (MI) Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2024 & 2030

IV. COMPETITION